October 14th 2024
Phase 1b findings may affirm the therapeutic potential of IMA203 for patients with previously treated metastatic melanoma.
September 17th 2024
September 5th 2024
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Tumor-Infiltrating Lymphocyte Therapy Advances Into Melanoma
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Investigators Are Assessing an Experimental Interleukin-2 Drug in Patients With Metastatic Melanoma
June 5th 2019A phase III study comparing the efficacy and safety of nivolumab plus an experimental interleukin-2–based drug vs nivolumab alone in patients with metastatic melanoma is now enrolling patients.
Will Adjuvant Pembrolizumab Be an Effective Therapy for High-Risk Melanoma?
June 4th 2019Investigators are now enrolling patients for a phase III trial, KEYNOTE-716, to assess the efficacy and safety of adjuvant pembrolizumab in adult and pediatric patients with surgically resected high-risk stage II melanoma.
ILLUMINATE 301 Will Study Experimental Immunotherapy for Patients With Advanced Melanoma
June 4th 2019Investigators are now enrolling for a phase III trial testing the experimental immunotherapy tilsotolimod plus ipilimumab in patients with advanced melanoma who have progressed on anti–PD-1 therapy.